Sandostatin LAR depot 30 MG KTS
Ended Awarded Last action
- Contract number
- SPE2DR26F0ZX0
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $17,715
Award facts
- Contract value 100% obligated
- $17,715.18 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $17,715.18 delivery order to Amerisourcebergen Drug Corp (UEI: KABZK8W6PQT3) on January 13, 2026, for the supply of Sandostatin LAR Depot 30 mg kits, with completion scheduled for January 14, 2026. This firm fixed-price delivery order represents a non-set-aside, competitively awarded contract executed through the company's existing pharmaceutical supply agreement. Amerisourcebergen Drug Corp, headquartered in Conshohocken, Pennsylvania, operates as a subsidiary of parent company Cencora, Inc. (doing business as Amerisourcebergen), and serves as a critical vendor in the federal medical procurement supply chain.
This delivery order falls under Amerisourcebergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (valued at $999,999,999.00 through December 2026), which provides a comprehensive global pharmaceutical support vehicle for military healthcare systems. The contract vehicle enables the company to supply an extensive range of pharmaceutical products, specialty medications, generic drugs, vaccines, and medical supplies to support Defense Health Agency operations and other federal healthcare systems worldwide. The Sandostatin LAR Depot product supplied under this order is a long-acting injectable medication used in endocrinology and gastroenterology treatments, reflecting the breadth of therapeutic domains covered under the broader pharmaceutical prime vendor arrangement.
Quick answers
Who was awarded contract SPE2DR26F0ZX0?
SPE2DR26F0ZX0 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 13, 2026.
How much is contract SPE2DR26F0ZX0 worth?
The government has obligated $17,715 on SPE2DR26F0ZX0.
Is contract SPE2DR26F0ZX0 an order under another contract?
Yes. SPE2DR26F0ZX0 is a delivery order under SPE2DR25D1205, an indefinite delivery contract.
Was contract SPE2DR26F0ZX0 competed?
The extent of competition for SPE2DR26F0ZX0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award